<div id="readability-page-1"><div>BOSTONandSTOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a strategic collaboration that establishes Sai’s Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA™ platform.Under this collaboration, Mabtech and Sai will jointly deliver advanced immunology assay services — including high-sensitivity multiplex cytokine and phenotyping workflows — powered by the EYRA platform installed at Sai’s Boston discovery site. This initiative accelerates access to next-generation immune profiling capabilities for biopharma and biotech companies working in immuno-oncology, vaccines, inflammation, and cellular therapy.“We’re excited to see EYRA placed at Sai Life Sciences and integrated into their US discovery operations,” said Kimberlee Parent, Head of US Operations at Mabtech. “This installation enables Sai to offer EYRA’s powerful, no-flow multiplex immunology readouts to their broad customer base, expanding access to high-quality, reproducible immune profiling. Together, Mabtech’s assay expertise and Sai’s strong discovery and translational capabilities create a compelling new service offering for researchers.”</div> The EYRA platform incorporates intuitive software, automation readiness, and simultaneous detection of dozens of analytes in a single run with minimal hands-on time. Originally developed through a long-term R&amp;D collaboration, EYRA overcomes key limitations of traditional flow-based and plate-based systems, enabling streamlined and scalable immune profiling workflows. “For our discovery clients, the ability to generate reliable, decision-enabling data early is critical,” said Maneesh Pingle, Head of Discovery Services at Sai Life Sciences. “By establishing our Boston site as a US execution hub for EYRA-enabled immunology workflows, we are strengthening Sai’s capability to support complex programs in immunology and immuno-oncology. This collaboration with Mabtech allows us to integrate advanced immune profiling seamlessly into broader discovery and translational strategies—helping teams move from biological hypothesis to confident development decisions faster.” Key elements of the collaboration include: • Joint service delivery of EYRA-based immunology panels and custom assays • Co-branded demonstrations and pilot programs at Sai Boston • Shared thought leadership and case study development • Integrated BD engagement supporting discovery through translational research <div>About Mabtech Mabtech is a Swedish life science tools company delivering high-quality immunoassays, reagents, and instrumentation to support advanced immunology research worldwide.About Sai Life Sciences Sai Life Sciences is a full-service CRDMO working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules and emerging modalities. With operations across India, the UK, and the US, Sai Life Sciences offers deep scientific expertise, world-class infrastructure, and a culture of excellence focused on quality, safety, and sustainability. For more details visit: www.sailife.com</div> Image: https://www.globenewswire.com/newsroom/ti?nf=OTY0NDIzMiM3Mzk1ODk1IzIyNTk3MzQ= Image: https://ml.globenewswire.com/media/OTYwZWExNDctMmM5MC00MWZhLWE5OWQtNmZmMjkyYWQyYjk2LTEyNzEyODQtMjAyNi0wMS0yOC1lbg==/tiny/SAI-LIFE-SCIENCES-LIMITED.png <pre>For further information, contact: Mabtech Jens Gertow, Chief Marketing Officer Email: Jens.Gertow@mabtech.com Sai Life Sciences Sriram Gopalakrishnan Email: Sriram.g@sailife.com</pre>Image: Primary Logo Source: SAI LIFE SCIENCES LIMITED</div>

Mabtech 和 Sai Life Sciences 宣佈了一項戰略合作，以利用 Sai 位於波士頓的場所通過 EYRA 平台增強免疫學研究。此次合作將為生物製藥和生物技術公司提供先進的免疫學檢測服務，包括多重細胞因子工作流程。EYRA 平台提供高效的免疫特徵分析能力，將先進技術整合到 Sai 的發現操作中。合作的關鍵要素包括聯合服務交付、共同品牌展示和共享思想領導，旨在加速免疫學和免疫腫瘤學項目的發展

Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site

fidelity

Caris Life Sciences

Origin Life Sciences

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 ETF - SPDR

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

基因免疫&健康關懷 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

基因改革 ETF - ARK

Mabtech 和 Sai Life Sciences 宣佈在 Sai 波士頓站點通過 EYRA 平台推進免疫學研究的戰略合作